In today’s briefing:
- Otsuka, Hirose Electric, Screen, Advantest: The Value Seeker Portfolio and NK Options
- Intuitive Surgical’s da Vinci Upgrade—How Far Can Procedure Growth Go in 2025?
- Quest Diagnostics: Focus On Implementation & Digital Integration to Improve Patient Satisfaction & Potentially Retaining Long-Term Customer Relationships!
- Novo Nordisk Boardroom Coup? Foundation Forces Complete Leadership Reset!
- Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
Otsuka, Hirose Electric, Screen, Advantest: The Value Seeker Portfolio and NK Options
- A compelling investment strategy focused on high-quality Japanese equities, selected for strong financial health and growth prospects. This approach targets companies offering stability and long-term appreciation.
- The portfolio emphasizes industrial, automation, pharma, and technology hardware sectors, balanced with a tactical volatility trading approach. This strategy aims to enhance returns while managing short-term market fluctuations.
- Otsuka Holdings is highlighted as a core pharma pick. Screen and Hirose Electric are strong value picks in manufacturing and electronic tech, contributing to the portfolio’s quality and value focus.
Intuitive Surgical’s da Vinci Upgrade—How Far Can Procedure Growth Go in 2025?
- Intuitive Surgical’s third-quarter 2025 results reflect significant operational successes as well as challenges to consider.
- Intuitive Surgical, a leader in robotic-assisted surgical platforms, demonstrated notable growth, driven by the adoption of its new da Vinci 5 system and ongoing expansion in international markets.
- However, the company also faces certain pressures, including economic conditions in some regions and competitive dynamics.
Quest Diagnostics: Focus On Implementation & Digital Integration to Improve Patient Satisfaction & Potentially Retaining Long-Term Customer Relationships!
- Quest Diagnostics reported strong results for the third quarter of 2025, with revenues reaching $2.82 billion, a 13.1% increase compared to the previous year.
- This growth was driven by a combination of organic expansion, contributions from acquisitions, and increased demand for the company’s clinical solutions.
- Organic revenue grew 6.8%, indicating positive momentum in the company’s core operations.
Novo Nordisk Boardroom Coup? Foundation Forces Complete Leadership Reset!
- Novo Nordisk A/S reported its financial results for the first quarter of 2025, showcasing strong growth across its operations, though facing certain challenges.
- The company delivered an 18% increase in sales and a 20% growth in operating profit, reflecting robust demand for its diabetes and obesity treatments.
- These positive results underscore the company’s ongoing market leadership, with approximately 46 million patients currently benefiting from its treatment solutions.
Psychedelics, the FDA, and PharmAla’s Strategic Approach Post-Lykos CRL
- FDA’s first-ever priority vouchers send out positive signals for psychedelics.
- Following up on our podcast discussion with Kadysh in June about the FDA’s proposed reforms, including the idea of a national priority voucher program, he highlighted the recent award of the first-ever priority vouchers to nine products, which included ketamine (a psychedelic-like compound) for US manufacturing.
- This means that anyone who applies to the FDA to manufacture ketamine in the US (currently approved for the treatment of treatment-resistant depression under the brand Spravato®) gets an “incredibly aggressive” two-month review timeline.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
